Commissioned in 2020, the DH2 site serves as a cornerstone for Asymchem’s carbapenem manufacturing, scaling from clinical supply to commercial tonnage. The facility integrates proprietary continuous flow ozonolysis capabilities, an engineering feat designed to improve safety profiles and minimize the company's carbon footprint. This shift toward continuous flow manufacturing remains a strategic priority across the organization's global network.

Dr. Hao Hong, Chairman and CEO of Asymchem Group, noted that the successful audit reinforces the company’s adherence to global quality standards, adding to a track record that spans regulators in the European Union, Japan, Australia, and North America. The firm currently manages a rigorous quality control environment, conducting over 100 regulatory inspections and roughly 200 customer audits annually. By leveraging a Quality by Design framework, the company maintains its focus on risk-based, data-driven manufacturing processes to support its international pharmaceutical and biotech clients.